<DOC>
	<DOCNO>NCT00035607</DOCNO>
	<brief_summary>This study investigate darbepoetin alfa treatment anemia patient non-myeloid cancer receive chemotherapy . Darbepoetin alfa recombinant protein stimulate production red blood cell . In study , darbepoetin alfa administer either injection skin ( subcutaneously ) directly vein ( intravenously ) .</brief_summary>
	<brief_title>Chemotherapy Related Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Diagnosed nonmyeloid malignancy Scheduled receive minimum additional 12 week chemotherapy time first dose study drug Screening hemoglobin concentration less equal 11.0g/dL ECOG performance status 0 2 Adequate renal liver function History seizure disorder Received recombinant human erythropoietin ( rHuEPO ) darbepoetin alfa therapy within 4 week study day 1 More 2 red blood cell transfusion within 4 week study day 1 , red blood cell transfusion within 14 day study day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>